MX2022002366A - Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente. - Google Patents

Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.

Info

Publication number
MX2022002366A
MX2022002366A MX2022002366A MX2022002366A MX2022002366A MX 2022002366 A MX2022002366 A MX 2022002366A MX 2022002366 A MX2022002366 A MX 2022002366A MX 2022002366 A MX2022002366 A MX 2022002366A MX 2022002366 A MX2022002366 A MX 2022002366A
Authority
MX
Mexico
Prior art keywords
fully
diabetic retinopathy
translationally modified
treatment
modified anti
Prior art date
Application number
MX2022002366A
Other languages
English (en)
Spanish (es)
Inventor
Everen Sherri Van
Jesse I Yoo
Samir Maganbhai Patel
Avanti Arvind Ghanekar
Kim Rees Irwin-Pack
Darin Thomas Curtiss
Stephen Joseph Pakola
Anthony Ray O''berry
Original Assignee
Regenxbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenxbio Inc filed Critical Regenxbio Inc
Publication of MX2022002366A publication Critical patent/MX2022002366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022002366A 2019-08-26 2020-08-25 Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente. MX2022002366A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962891799P 2019-08-26 2019-08-26
US201962902352P 2019-09-18 2019-09-18
US202063004258P 2020-04-02 2020-04-02
PCT/US2020/047733 WO2021041373A1 (en) 2019-08-26 2020-08-25 Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab

Publications (1)

Publication Number Publication Date
MX2022002366A true MX2022002366A (es) 2022-07-19

Family

ID=72473961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002366A MX2022002366A (es) 2019-08-26 2020-08-25 Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.

Country Status (11)

Country Link
US (1) US20220280608A1 (https=)
EP (1) EP4021936A1 (https=)
JP (1) JP2022545967A (https=)
KR (1) KR20220051246A (https=)
CN (1) CN114502197A (https=)
AU (1) AU2020336314A1 (https=)
BR (1) BR112022003811A2 (https=)
CA (1) CA3149401A1 (https=)
IL (1) IL290863A (https=)
MX (1) MX2022002366A (https=)
WO (1) WO2021041373A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2024178225A1 (en) * 2023-02-22 2024-08-29 Cornell University Gene therapy mediated angiogenesis to enhance survival of transplanted fat
WO2025081143A1 (en) * 2023-10-14 2025-04-17 City Labs, Inc. Radioluminescent eye device for modulation of photoreceptor metabolism

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804561B1 (en) 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
JP2003524368A (ja) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白
JP2001514007A (ja) 1997-08-27 2001-09-11 アリアド ジーン セラピューティクス インコーポレイテッド キメラ転写アクチベーター、ならびにそれに関連する組成物および使用
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
JP2002503667A (ja) 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
WO2012057363A1 (ja) 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
US9393370B2 (en) 2012-05-24 2016-07-19 Altaviz Llc Viscous fluid injector
CA2905952A1 (en) 2013-03-13 2014-10-02 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
CN106232618A (zh) 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10064752B2 (en) 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
US11071643B2 (en) 2014-11-28 2021-07-27 Visionisti Oy Ocular therapeutics tool
USD878575S1 (en) 2015-11-24 2020-03-17 Visionisti Oy Hand operated medical instrument
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
KR20240005973A (ko) * 2016-04-15 2024-01-12 리젠엑스바이오 인크. 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료
EP3687464A4 (en) 2017-09-27 2021-09-29 REGENXBIO Inc. TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST-TRANSLATION MODIFIED ANTI-VEGF FAB
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
US11071824B2 (en) 2017-11-04 2021-07-27 Altaviz, Llc Injection devices and methods for making and using them
US10912883B2 (en) 2017-11-04 2021-02-09 Altaviz, Llc Gas-powered fluid injection system

Also Published As

Publication number Publication date
AU2020336314A1 (en) 2022-04-07
CN114502197A (zh) 2022-05-13
CA3149401A1 (en) 2021-03-04
KR20220051246A (ko) 2022-04-26
WO2021041373A1 (en) 2021-03-04
TW202122419A (zh) 2021-06-16
IL290863A (en) 2022-04-01
EP4021936A1 (en) 2022-07-06
BR112022003811A2 (pt) 2022-11-16
JP2022545967A (ja) 2022-11-01
US20220280608A1 (en) 2022-09-08
WO2021041373A8 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
MX2022002366A (es) Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.
Rahimy et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema
Vajaranant et al. Visual acuity and intraocular pressure after Descemet's stripping endothelial keratoplasty in eyes with and without preexisting glaucoma
Nguyen et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
Spitzer et al. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema
Chang et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration
Freund et al. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab
Pichi et al. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms
Rehak et al. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study)
Berger et al. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME
Hassanaly et al. Outcomes following Boston type 1 keratoprosthesis implantation in aniridia patients at the University of Montreal
Patil et al. Corneal changes in childhood glaucoma
Cagatay et al. Long–Term Comparison of Fibrin Tissue Glue and Vicryl Suture in Conjunctival Autografting for Pterygium Surgery
Ogawa et al. Aetiology-specific comparison of long-term outcome of deep anterior lamellar keratoplasty for corneal diseases
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
Dohlman et al. Bevacizumab in high-risk corneal transplantation: a pilot multicenter prospective randomized control trial
Lipp et al. Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis
Raecker et al. Long-term keratometric changes after penetrating keratoplasty for keratoconus and Fuchs endothelial dystrophy
Cho et al. Hemorrhagic complications after intravitreal ranibizumab injection for polypoidal choroidal vasculopathy
Ozturk et al. Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema
Eibenberger et al. Effects of intravitreal dexamethasone implants on retinal oxygen saturation, vessel diameter, and retrobulbar blood flow velocity in ME secondary to RVO
Vasudev et al. Intravitreal bevacizumab for neovascular glaucoma
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
AR119834A1 (es) TRATAMIENTO DE RETINOPATÍA DIABÉTICA CON Fab ANTI-VEGF COMPLETAMENTE HUMANO MODIFICADO DESPUÉS DE LA TRADUCCIÓN
A Das et al. Combined treatment modalities for age related macular degeneration